From owner-cypherpunks@Algebra.COM  Wed Aug 14 17:48:05 2002
Return-Path: <owner-cypherpunks@Algebra.COM>
Received: from pacific-carrier-annex.mit.edu (PACIFIC-CARRIER-ANNEX.MIT.EDU [18.7.21.83])
	by positron.jfet.org (8.11.6/8.9.3) with ESMTP id g7ELm5029703
	for <rsw@opamp.org>; Wed, 14 Aug 2002 17:48:05 -0400
Received: from ak47.algebra.com ([209.120.156.51])
	by pacific-carrier-annex.mit.edu (8.9.2/8.9.2) with ESMTP id RAA20972
	for <rsw@mit.edu>; Wed, 14 Aug 2002 17:48:04 -0400 (EDT)
Received: from ak47.algebra.com (majordom@localhost [127.0.0.1])
	by ak47.algebra.com (8.12.1/8.12.1) with ESMTP id g7EJb3Nm021469
	for <cypherpunks-outgoing@ak47.algebra.com>; Wed, 14 Aug 2002 14:37:03 -0500
Received: (from majordom@localhost)
	by ak47.algebra.com (8.12.1/8.12.1/Submit) id g7EJb3Yw021468
	for cypherpunks-outgoing; Wed, 14 Aug 2002 14:37:03 -0500
X-Authentication-Warning: ak47.algebra.com: majordom set sender to owner-cypherpunks@Algebra.COM using -f
Received: from locust.minder.net (locust.minder.net [66.92.53.74])
	by ak47.algebra.com (8.12.1/8.12.1) with ESMTP id g7EJaxNm021450
	for <cypherpunks@algebra.com>; Wed, 14 Aug 2002 14:37:00 -0500
Received: from waste.minder.net (daemon@waste [66.92.53.73])
	by locust.minder.net (8.11.6/8.11.6) with ESMTP id g7EJasJ29851
	for <cypherpunks@algebra.com>; Wed, 14 Aug 2002 15:36:55 -0400 (EDT)
	(envelope-from cpunks@waste.minder.net)
Received: (from cpunks@localhost)
	by waste.minder.net (8.11.6/8.11.6) id g7EJasE10893
	for cypherpunks@algebra.com; Wed, 14 Aug 2002 15:36:54 -0400
Received: (from majordom@localhost)
	by waste.minder.net (8.11.6/8.11.6) id g7EJZTF10809
	for cypherpunks-outgoing; Wed, 14 Aug 2002 15:35:29 -0400
Received: from locust.minder.net (locust.minder.net [66.92.53.74])
	by waste.minder.net (8.11.6/8.11.6) with ESMTP id g7EJZSR10805
	for <cypherpunks@minder.net>; Wed, 14 Aug 2002 15:35:28 -0400
Received: from www.nex.net.au (www2.nex.com.au [203.24.143.63])
	by locust.minder.net (8.11.6/8.11.6) with ESMTP id g7EJZRJ29821
	for <cypherpunks@minder.net>; Wed, 14 Aug 2002 15:35:27 -0400 (EDT)
	(envelope-from profrv@nex.net.au)
Received: from www2.nex.net.au [203.24.143.63] by www.nex.net.au
  (SMTPD32-6.06) id A0C834AA01A8; Thu, 15 Aug 2002 05:34:32 +1000
Received: FROM profrv.nex.net.au BY www2.nex.net.au ; Thu Aug 15 05:34:25 2002 +1000
Message-Id: <5.1.0.14.0.19990503200432.009d1a90@mail.nex.net.au>
X-Sender: profrv@mail.nex.net.au
X-Mailer: QUALCOMM Windows Eudora Version 5.1
Date: Mon, 03 May 1999 20:05:39 -0700
To: cypherpunks@minder.net
From: Matthew X <profrv@nex.net.au>
Old-Subject: Dr Rat.
Mime-Version: 1.0
Content-Type: multipart/alternative;
	boundary="=====================_18416534==_.ALT"
Old-Subject:  Dr Rat.
Subject:   Dr Rat.
X-Algebra: <A HREF=http://www.algebra.com>Algebra</A>
Sender: owner-cypherpunks@Algebra.COM
Precedence: bulk
X-Mailing-List: cypherpunks@algebra.com
X-List-Admin: ichudov@algebra.com
X-Loop: cypherpunks@algebra.com
Status: O
Content-Length: 5906
Lines: 113


--=====================_18416534==_.ALT
Content-Type: text/plain; charset="iso-8859-1"; format=flowed
Content-Transfer-Encoding: quoted-printable

Diabetes drug prematurely tested on humans

TIMES NEWS NETWORK [ WEDNESDAY, AUGUST 14, 2002 12:04:59 PM ]
HYDERABAD: Ragaglitazar, the controversial dual-acting insulin sensitiser=20
developed by Dr Reddy=92s Labs (DRL), was tested on at least 135 human=
 beings=20
at the Nizam=92s Institute of Medical Sciences (Nims) even before trials on=
=20
rats and mice were completed.
The experts realised the dangerous side-effects of the drug only after Novo=
=20
Nordisk, the Scandinavian company assigned to develop the medicine, stopped=
=20
testing on July 22, after the experimental rats and mice began developing=20
tumours and symptoms of cancer.
The tests of the drug at Nims continued for well over six months, sources=20
in the hospital confirmed. The trials on human beings =97 phase-III of the=
=20
drug test =97 were conducted under the supervision of the Diabetic School of=
=20
the hospital. The sources insisted that trials conducted by them were=20
approved by the Medical Council of India and the Drug Controller-General of=
=20
India.
However, it is not known if any or all of the 135 human guinea pigs at Nims=
=20
were informed that they were being administered a yet-to-be proven diabetes=
=20
drug. It is also not clear if they were told that the drug was being=20
simultaneously tested on rats and mice.
Dr. Reddy=92s Labs, though, has disowned the phase-III trials, saying it had=
=20
licensed the drug for further development to Novo Nordisk.
=93Testing of yet-to-be proven and potentially dangerous drugs on human=20
beings is common here. Our hospitals are places where patients take=20
medicines administered to them without asking a question. And, in the=20
course of a trial, if a patient dies, all the doctor does is change the=20
dosage for the others and continue with the test,=94 a source said.
=93This is not the first time that an unproven drug has been tested on human=
=20
beings, sometimes perforce in the city,=94 the sources added. Meanwhile,=20
government sources said they were unaware of the tests conducted by Nims=20
and were at a loss to explain anything about the trial.
Ragaglitazar, codenamed DRF 2725 and NN662, was developed by DRL. After=20
carrying out preliminary animal toxicology studies, DRL sold the drug to=20
Novo in 1998 for further development and commercialisation.
To ally fears in those who participated in the abortive trial, both the=20
Hyderabad-based laboratory and Novo Nordisk claim that though the=20
anti-diabetes drug caused =93bladder tumours in rats and in one mouse,=94=20
potential risk to the trial participants is =91very small=92.
Related Stories:
http://timesofindia.indiatimes.com/articleshow.asp?artid=3D19049806

--=====================_18416534==_.ALT
Content-Type: text/html; charset="iso-8859-1"
Content-Transfer-Encoding: quoted-printable

<html>
Diabetes drug prematurely tested on humans <br>
<br>
TIMES NEWS NETWORK [ WEDNESDAY, AUGUST 14, 2002 12:04:59 PM ] <br>
HYDERABAD: Ragaglitazar, the controversial dual-acting insulin sensitiser
developed by Dr Reddy=92s Labs (DRL), was tested on at least 135 human
beings at the Nizam=92s Institute of Medical Sciences (Nims) even before
trials on rats and mice were completed.<br>
The experts realised the dangerous side-effects of the drug only after
Novo Nordisk, the Scandinavian company assigned to develop the medicine,
stopped testing on July 22, after the experimental rats and mice began
developing tumours and symptoms of cancer.<br>
The tests of the drug at Nims continued for well over six months, sources
in the hospital confirmed. The trials on human beings =97 phase-III of the
drug test =97 were conducted under the supervision of the Diabetic School
of the hospital. The sources insisted that trials conducted by them were
approved by the Medical Council of India and the Drug Controller-General
of India.<br>
However, it is not known if any or all of the 135 human guinea pigs at
Nims were informed that they were being administered a yet-to-be proven
diabetes drug. It is also not clear if they were told that the drug was
being simultaneously tested on rats and mice.<br>
Dr. Reddy=92s Labs, though, has disowned the phase-III trials, saying it
had licensed the drug for further development to Novo Nordisk.<br>
=93Testing of yet-to-be proven and potentially dangerous drugs on human
beings is common here. Our hospitals are places where patients take
medicines administered to them without asking a question. And, in the
course of a trial, if a patient dies, all the doctor does is change the
dosage for the others and continue with the test,=94 a source said.<br>
=93This is not the first time that an unproven drug has been tested on
human beings, sometimes perforce in the city,=94 the sources added.
Meanwhile, government sources said they were unaware of the tests
conducted by Nims and were at a loss to explain anything about the
trial.<br>
Ragaglitazar, codenamed DRF 2725 and NN662, was developed by DRL. After
carrying out preliminary animal toxicology studies, DRL sold the drug to
Novo in 1998 for further development and commercialisation. <br>
To ally fears in those who participated in the abortive trial, both the
Hyderabad-based laboratory and Novo Nordisk claim that though the
anti-diabetes drug caused =93bladder tumours in rats and in one mouse,=94
potential risk to the trial participants is =91very small=92.<br>
<b>Related Stories:</b> <br>
<a href=3D"http://timesofindia.indiatimes.com/articleshow.asp?artid=3D190498=
06"=
 eudora=3D"autourl">http://timesofindia.indiatimes.com/articleshow.asp?artid=
=3D</a><a=
 href=3D"http://timesofindia.indiatimes.com/articleshow.asp?artid=3D19049806=
" eudora=3D"autourl">19049806<br>
</a></html>

--=====================_18416534==_.ALT--

